The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial

Abstract

Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients. Clostridium butyricum (CB) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of CB in treating IBS is still unknown. This prospective, multi-centre, randomized, double-blind, placebo-controlled trial aimed to assess the efficacy and safety of CB in treating diarrhea-predominant IBS (IBS-D) and analyze the fecal microbiota after treatment. Two hundred patients with IBS-D were recruited and were given CB or placebo for 4 weeks. End points included change from baseline in IBS symptoms, quality of life, stool consistency and frequency. Compared with placebo, CB is effective in improving the overall IBS-D symptoms (−62.12 ± 74.00 vs. −40.74 ± 63.67, P = 0.038) as well as quality of life (7.232 ± 14.06 vs. 3.159 ± 11.73, P = 0.032) and stool frequency (−1.602 ± 1.416 vs. −1.086 ± 1.644, P = 0.035). The responder rates are found higher in CB compared with the placebo (44.76% vs. 30.53%, P = 0.042). The change in fecal microbiota was analyzed and function pathways of CB in treating IBS-D were predicted. In conclusion, CB improves overall symptoms, quality of life and stool frequency in IBS-D patients and is considered to be used as a probiotics in treating IBS-D clinically.

Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis

“…Overall, there were a total of 4,321 patients with IBS, of which 59.5% were female. In terms of IBS subtypes, six RCTs included patients with IBS-D, one with IBS-C and one with both IBS-D and IBS-M. [26][27][28][29][30][31][32][33] The remaining trials included patients with all subtypes. With regards to location, the majority of the trials were conducted in Europe (n = 18) followed by Asia (n = 13).…”

“…With regards to location, the majority of the trials were conducted in Europe (n = 18) followed by Asia (n = 13). [26][27][28][29][30][31][32][33] The remaining two RCTs were based in South Africa and the USA, respectively. 34,35 The Rome I criteria were used for diagnosis in two trials, while the Rome II criteria were used in 11 trials.…”

“…[32][33][34][40][41][42][43][44][45][46][47][48][49] The rest of the trials utilised the Rome III criteria. [26][27][28][29][30][31][35][36][37][38][39][50][51][52][53][54][55][56][57][58] In terms of intervention, three trials investigated prebiotics (partially-hydrolysed guar gum and fructooligosaccharides) and three investigated synbiotics. 38,40,42,50,51 The remaining 27 RCTs evaluated probiotics.…”

Mulberry juice freeze-dried powder attenuates the disease severity by the maintaining of colon mucosa in mice with DSS-induced acute colitis

“…Some Clostridium species are considered as pathogens, such as C. difficile [51]. On the other hand, C. butyricum, which belongs to C. perfringens group, is probiotic bacteria able to reduce intestinal inflammation by improving the mucosal barrier function and modulating immune responses [52].…”

Complete Genome Sequence of Clostridium butyricum Strain DKU_butyricum 4-1, Isolated from Infant Feces

“…Probiotic bacteria are live microorganisms that give a health benefit to the host. In practice, probiotics can improve the balance of the intestinal microbiota ecosystem of the host, which is beneficial in treating a variety of infant conditions, including infant diarrhea, upset stomach, and eczema, and many health conditions of preterm infants (2,3). Here, we present the complete annotated genome sequence of Clostridium butyricum strain DKU_butyricum 4-1, isolated from infant feces.…”